Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lacosamide versus active comparator for electroencephalographic neonatal seizures
2020-001066-10Phase 3
- Sponsor
- UCB
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in neonatal seizure comparing Lacosamide with Active comparator chosen by standard of care (2 arms). Primary endpoint: Change in seizure burden.
02
Drugs
lacosamide
03
Conditions
neonatal seizure
Beyond the preview
Go deeper on 2020-001066-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001066-10.